comparemela.com

Page 4 - Beth Faiman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

CAR-T Cell Therapy Overview

Dr Matous leads a conversation regarding CAR T-cell therapy for treating multiple myeloma.

Kirollos hannaZahra mahmoudjafariBeth faimanJeffrey matousSteph curryMultiple myelomaIdecabtagene vicleucelCiltacabtagene autoleucel

Payer Considerations in Treatment of RRMM

A panel of multiple myeloma experts discuss costs associated with relapsed/refractory disease.

Jeffrey matousBeth faimanZahra mahmoudjafariKirollos hannaMultiple myelomaCart cell therapy

The RRMM Patient Journey: Part 2

Treatment considerations for relapsing multiple myeloma is discussed by key opinion leaders.

United statesKirollos hannaZahra mahmoudjafariJeffrey matousBeth faimanInternational myeloma foundationAfrican americanAfrican americansMultiple myelomaDream studyB cellB cell maturationB cell maturation agentCar t

Overview of Relapsed / Refractory Multiple Myeloma

Jeffrey Matous, MD, leads a panel discussion surrounding the use of bispecifics treatment of relapsed / refractory multiple myeloma.

United statesKirollos hannaHanna kirollosJeffrey matousBeth faimanZahra mahmoudjafariUniversity of kansas cancer centerColorado blood cancer institute in denverPeer exchangeMayo clinic college of medicineBispecifics in relapsedRefractory multipleColorado blood cancer instituteCleveland clinicClinical pharmacy managerKansas cancer

International Myeloma Foundation launches #MYelomaSTORY campaign

WITH the International Myeloma Foundation (IMF) at the forefront, Myeloma Awareness/Action Month is held every year for the whole month of March to encourage individuals and groups to take actions.

United statesBoca ratonYelak biruJoseph mikhaelBeth faimanInternational myeloma foundationJamaica multiple myeloma support groupAction monthMyeloma action monthMyeloma actionPatient action letterChief science officer dr brianFamily seminarMedical officer dr joseph mikhaelMarch action monthSupport group challenge

vimarsana © 2020. All Rights Reserved.